US Labels India, Pakistan, China Among Drug Transit Countries
In a “Presidential Determination” submitted to the U.S. Congress, President Donald Trump named 23 countries as major drug transit or illicit drug-producing nations. Among them are India, Pakistan, China, Afghanistan, and Burma (Myanmar).
Reasoning Behind the Designation
The determination states that these countries are involved in manufacturing or distribution of illicit drugs or precursor chemicals which threaten U.S. public health and safety.
“Failed Demonstrably” List
Separately, Trump designated Afghanistan, Bolivia, Burma, Colombia, and Venezuela as having “failed demonstrably” in their counternarcotics obligations in the past year. This status may affect U.S. foreign aid and cooperation.
Reactions & Implications
Officials in the countries named — including India and Pakistan — have not immediately reacted in depth. Analysts observe this move could lead to increased diplomatic pressure, with possible consequences for funding, trade, and international cooperation around drug production and trafficking.
